Dataset Information


Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system.

ABSTRACT: DNA-based gene therapy has considerable therapeutic potential, but the challenges associated with delivery continue to limit progress. Messenger RNA (mRNA) has the potential to provide for transient production of therapeutic proteins, without the need for nuclear delivery and without the risk of insertional mutagenesis. Here we describe the sustained delivery of therapeutic proteins in vivo in both rodents and non-human primates via nanoparticle-formulated mRNA. Nanoparticles formulated with lipids and lipid-like materials were developed for delivery of two separate mRNA transcripts encoding either human erythropoietin (hEPO) or factor IX (hFIX) protein. Dose-dependent protein production was observed for each mRNA construct. Upon delivery of hEPO mRNA in mice, serum EPO protein levels reached several orders of magnitude (>125?000-fold) over normal physiological values. Further, an increase in hematocrit (Hct) was established, demonstrating that the exogenous mRNA-derived protein maintained normal activity. The capacity of producing EPO in non-human primates via delivery of formulated mRNA was also demonstrated as elevated EPO protein levels were observed over a 72-h time course. Exemplifying the possible broad utility of mRNA drugs, therapeutically relevant amounts of human FIX (hFIX) protein were achieved upon a single intravenous dose of hFIX mRNA-loaded lipid nanoparticles in mice. In addition, therapeutic value was established within a hemophilia B (FIX knockout (KO)) mouse model by demonstrating a marked reduction in Hct loss following injury (incision) to FIX KO mice.


PROVIDER: S-EPMC5059749 | BioStudies | 2016-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5347596 | BioStudies
2015-01-01 | S-EPMC4869688 | BioStudies
2020-01-01 | S-EPMC7355334 | BioStudies
2017-01-01 | S-EPMC5473850 | BioStudies
1000-01-01 | S-EPMC3392991 | BioStudies
2016-01-01 | S-EPMC4891223 | BioStudies
2008-01-01 | S-EPMC2954682 | BioStudies
1000-01-01 | S-EPMC5552065 | BioStudies
2010-01-01 | S-EPMC2945768 | BioStudies
2018-01-01 | S-EPMC6371630 | BioStudies